Immunotherapy. 2011;3(9):1075-1086. MIP-1β release has also been observed for CD56 neg NK cells from patients with HCV infection. The above results suggest that the aberrant CD56 neg NK subset ...

A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells. CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other ...

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...